StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Oppenheimer on Compass Pathways (CMPS) FDA Grant: 'reinforcing our conviction considering the earlier launch timeline for COMP360 in TRD'
April 24, 2026 1:24 PM
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $20.00 price target on Compass Pathways (NASDAQ: CMPS).The analyst comments "We ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
TD Cowen on Compass Pathways (CMPS) FDA Grant: 'meaningful positive and expected in light of last Saturday’s Executive Order'
April 24, 2026 3:41 PM
Morgan Stanley on Compass Pathways (CMPS): 'we view today’s update as incrementally encouraging'
April 24, 2026 1:06 PM
Compass Pathways receives FDA rolling review for psychedelic depression drug
April 24, 2026 10:37 AM
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
April 24, 2026 10:37 AM
FDA advances psychedelic drug studies for mental health treatment
April 24, 2026 9:10 AM
B.Riley Starts Compass Pathways (CMPS) at Buy
April 24, 2026 3:49 AM
